Effect of Water Molecules on the Activating S810L Mutation of the Mineralocorticoid Receptor
暂无分享,去创建一个
Mitsunori Ikeguchi | Masateru Ohta | Toru Ekimoto | Kei Takedomi | K. Takedomi | M. Ikeguchi | Toru Ekimoto | M. Ohta
[1] B. O’Malley,et al. Molecular mechanisms of action of steroid/thyroid receptor superfamily members. , 1994, Annual review of biochemistry.
[2] Junmei Wang,et al. Development and testing of a general amber force field , 2004, J. Comput. Chem..
[3] Zbigniew Dauter,et al. Molecular basis of agonism and antagonism in the oestrogen receptor , 1997, Nature.
[4] B. Rossier,et al. Aldosterone regulation of gene transcription leading to control of ion transport. , 1992, Hypertension.
[5] Tobias Hüfner-Wulsdorf,et al. Role of Water Molecules in Protein-Ligand Dissociation and Selectivity Discrimination: Analysis of the Mechanisms and Kinetics of Biomolecular Solvation Using Molecular Dynamics , 2020, J. Chem. Inf. Model..
[6] Timothy M Willson,et al. A Ligand-mediated Hydrogen Bond Network Required for the Activation of the Mineralocorticoid Receptor*[boxs] , 2005, Journal of Biological Chemistry.
[7] J. Fagart,et al. Sulfhydryl groups are involved in the binding of agonists and antagonists to the human mineralocorticoid receptor , 1996, The Journal of Steroid Biochemistry and Molecular Biology.
[8] F. J. Luque,et al. Shielded hydrogen bonds as structural determinants of binding kinetics: application in drug design. , 2011, Journal of the American Chemical Society.
[9] M. Agarwal,et al. General overview of mineralocorticoid hormone action. , 1999, Pharmacology & therapeutics.
[10] W. L. Jorgensen,et al. Comparison of simple potential functions for simulating liquid water , 1983 .
[11] T. Nyrönen,et al. Three-dimensional structure-activity relationships of nonsteroidal ligands in complex with androgen receptor ligand-binding domain. , 2005, Journal of medicinal chemistry.
[12] M. Makishima,et al. 2-Methylene 19-nor-25-dehydro-1alpha-hydroxyvitamin D3 26,23-lactones: synthesis, biological activities and molecular basis of passive antagonism. , 2008, Bioorganic & medicinal chemistry.
[13] G. Piwien-Pilipuk,et al. Modification of an essential amino group in the mineralocorticoid receptor evidences a differential conformational change of the receptor protein upon binding of antagonists, natural agonists and the synthetic agonist 11,19-oxidoprogesterone. , 2002, Biochimica et biophysica acta.
[14] P. Kollman,et al. Automatic atom type and bond type perception in molecular mechanical calculations. , 2006, Journal of molecular graphics & modelling.
[15] M Carlquist,et al. Structural insights into the mode of action of a pure antiestrogen. , 2001, Structure.
[16] R. Evans,et al. The steroid and thyroid hormone receptor superfamily. , 1988, Science.
[17] André Fischer,et al. Ligand Pathways in Nuclear Receptors , 2019, J. Chem. Inf. Model..
[18] J. Edwards,et al. 5-benzylidene-1,2-dihydrochromeno[3,4-f]quinolines as selective progesterone receptor modulators. , 2003, Journal of medicinal chemistry.
[19] David A. Agard,et al. Structural characterization of a subtype-selective ligand reveals a novel mode of estrogen receptor antagonism , 2002, Nature Structural Biology.
[20] Hideki Matsui,et al. Identification of benzoxazin-3-one derivatives as novel, potent, and selective nonsteroidal mineralocorticoid receptor antagonists. , 2011, Journal of medicinal chemistry.
[21] P. Sigler,et al. Activating mineralocorticoid receptor mutation in hypertension exacerbated by pregnancy. , 2000, Science.
[22] V. Lin,et al. Exploring Flexibility of Progesterone Receptor Ligand Binding Domain Using Molecular Dynamics , 2016, PloS one.
[23] J D Baxter,et al. The nuclear hormone receptor gene superfamily. , 1995, Annual review of medicine.
[24] C. Hellal-Levy,et al. Mechanistic aspects of mineralocorticoid receptor activation. , 2000, Kidney international.
[25] E. Baulieu,et al. Differential intracellular localization of human mineralocorticosteroid receptor on binding of agonists and antagonists. , 1994, The Biochemical journal.
[26] Vincent Le Guilloux,et al. Fpocket: An open source platform for ligand pocket detection , 2009, BMC Bioinformatics.
[27] M. Kawata,et al. Dynamic changes in subcellular localization of mineralocorticoid receptor in living cells: in comparison with glucocorticoid receptor using dual-color labeling with green fluorescent protein spectral variants. , 2001, Molecular endocrinology.
[28] A. Vandewalle,et al. Identification of steroid ligands able to inactivate the mineralocorticoid receptor harboring the S810L mutation responsible for a severe form of hypertension , 2004, Molecular and Cellular Endocrinology.
[29] M. Lombès,et al. Ligand-induced conformational change in the human mineralocorticoid receptor occurs within its hetero-oligomeric structure. , 1996, The Biochemical journal.
[30] J. Fagart,et al. Structural determinants of ligand binding to the mineralocorticoid receptor , 2012, Molecular and Cellular Endocrinology.
[31] C. Simmerling,et al. ff14SB: Improving the Accuracy of Protein Side Chain and Backbone Parameters from ff99SB. , 2015, Journal of chemical theory and computation.
[32] J. Fagart,et al. The mineralocorticoid activity of progesterone derivatives depends on the nature of the C18 substituent. , 1995, Endocrinology.
[33] T. N. Bhat,et al. The Protein Data Bank , 2000, Nucleic Acids Res..
[34] C. Gomez-Sanchez,et al. Specific hydroxylations determine selective corticosteroid recognition by human glucocorticoid and mineralocorticoid receptors , 1999, FEBS letters.
[35] Dan Li,et al. Structural Diversity of Ligand-Binding Androgen Receptors Revealed by Microsecond Long Molecular Dynamics Simulations and Enhanced Sampling. , 2016, Journal of chemical theory and computation.
[36] M. Lambert,et al. Activation of nuclear receptors: a perspective from structural genomics. , 2003, Structure.
[37] Woody Sherman,et al. Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments , 2013, Journal of Computer-Aided Molecular Design.
[38] J. Gustafsson,et al. Activation functions 1 and 2 of nuclear receptors: molecular strategies for transcriptional activation. , 2003, Molecular endocrinology.
[39] M. Lombès,et al. Finerenone Impedes Aldosterone-dependent Nuclear Import of the Mineralocorticoid Receptor and Prevents Genomic Recruitment of Steroid Receptor Coactivator-1* , 2015, The Journal of Biological Chemistry.
[40] H. Gronemeyer,et al. Nuclear receptor ligand-binding domains: three-dimensional structures, molecular interactions and pharmacological implications. , 2000, Trends in pharmacological sciences.
[41] P. Fuller,et al. Mineralocorticoid action , 2000, Steroids.
[42] Victor Guallar,et al. Ligand Binding Mechanism in Steroid Receptors: From Conserved Plasticity to Differential Evolutionary Constraints. , 2015, Structure.
[43] Ly Le,et al. Steered Molecular Dynamics Simulation in Rational Drug Design , 2018, J. Chem. Inf. Model..
[44] M. Lombès,et al. A new strategy for selective targeting of progesterone receptor with passive antagonists. , 2013, Molecular endocrinology.
[45] J. Gies,et al. Drugs and their molecular targets: an updated overview , 2008, Fundamental & clinical pharmacology.
[46] D. Moras,et al. Antagonism in the human mineralocorticoid receptor , 1998, The EMBO journal.
[47] Alexander Hillisch,et al. A New Mode of Mineralocorticoid Receptor Antagonism by a Potent and Selective Nonsteroidal Molecule* , 2010, The Journal of Biological Chemistry.
[48] Berk Hess,et al. GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputers , 2015 .
[49] E. Baulieu,et al. Differences between aldosterone and its antagonists in binding kinetics and ligand-induced hsp90 release from mineralocorticosteroid receptor , 1992, The Journal of Steroid Biochemistry and Molecular Biology.
[50] Norma Roxana Carina Alves,et al. Structural Insights into the Ligand Binding Domain of the Glucocorticoid Receptor: A Molecular Dynamics Study , 2019, J. Chem. Inf. Model..